CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation: Time for a Personalized Approach?

J Cardiovasc Pharmacol. 2022 Feb 1;79(2):159-160. doi: 10.1097/FJC.0000000000001179.
No abstract available

Publication types

  • Comment

MeSH terms

  • Clopidogrel
  • Cytochrome P-450 CYP2C19 / genetics
  • Genotype
  • Humans
  • Percutaneous Coronary Intervention* / adverse effects
  • Platelet Aggregation Inhibitors / adverse effects
  • Stents / adverse effects
  • Ticlopidine* / adverse effects

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticlopidine